6 completed, 3 terminated, 1 unknown. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Terminated 3, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow brivanib: new trials by email Literature Review of brivanib trials Research Report on brivanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer niraparib combined with brivanib, niraparib combined with toripalimab - Cervical Cancer | Phase 2 | Unknown | Chongqing University Cancer Hospital | 38 | 2020-05-08 | 2021-05-21 |
| MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Zai Lab (Shanghai) Co., Ltd. | 89 | 2020-04-20 | 2024-07-23 |
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC Brivanib 800 mg, QD, Brivanib 400 mg, BID - Hepatocellular Carcinoma (HCC) | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 90 | 2017-05-17 | 2019-09-04 |
| Brivanib Metastatic Renal Cell Carcinoma Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250 - Renal Cell Carcinoma | Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 10 | 2011-11-01 | 2021-04-13 |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF Brivanib, Irinotecan - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2011-08-01 | 2020-09-03 |
| Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Brivanib Alaninate, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2011-04-04 | 2019-03-20 |
| Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Brivanib Alaninate, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 45 | 2009-07-06 | 2017-12-06 |
| Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types brivanib, Placebo - Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma | Phase 2 | Completed | Bristol-Myers Squibb | 597 | 2008-06-01 | 2015-10-09 |
| Phase I/II Combination With Irinotecan- Erbitux Cetuximab, Irinotecan, Brivanib - Metastatic Colorectal Cancer (MCRC) | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 38 | 2008-05-01 | 2015-11-04 |
| A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer brivanib (active) - Hepatocellular Carcinoma (HCC) | Phase 2 | Completed | Bristol-Myers Squibb | 137 | 2006-12-31 | 2023-12-01 |
Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Uterine Cervical Neoplasms (2) · Acrocephalosyndactylia (1) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Sarcoma (1)
Bristol-Myers Squibb (3) · Gynecologic Oncology Group (2) · Zai Lab (Shanghai) Co., Ltd. (2) · Abramson Cancer Center at Penn Medicine (1) · Chongqing University Cancer Hospital (1) · M.D. Anderson Cancer Center (1)
United States (7) · China (3) · Argentina (2) · France (2) · South Korea (2) · Belgium (1) · Canada (1) · Denmark (1) · Germany (1) · Hong Kong (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Philippines (1) · Poland (1)
John K Chan (1) · Matthew Powell (1) · Michael Overman, MD (1) · Qi Zhou, Ph.D. (1) · Stephen Keefe, MD (1) · ZhengGang Ren, PhD (1)
PMID 16110319, PMID 21349999, PMID 23552472, PMID 24474817, PMID 25326159, PMID 25592089, PMID 25651787, PMID 28728751, PMID 29365411, PMID 37185961
U10CA027469 (2), U10CA180868 (2)